Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells

International Journal of Gynecological Cancer

Volumn 19, Issue 2, 2009, Pages 214-222

  Henic, Emir ^a   Noskova, Vera ^a   Høyer Hansen, Gunilla ^b   Hansson, Stefan ^a   Casslén, Bertil ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Cell migration; GPR30; Lipid rafts; Membrane ER; OVCAR 3; UPAR

Indexed keywords

DETERGENT; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; ESTROGEN RECEPTOR; GPER PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; DEGRADATION; ENDOPLASMIC RETICULUM; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LIPID RAFT; NUCLEOTIDE SEQUENCE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLUBILIZATION; STIMULATION; ADENOCARCINOMA; BIOSYNTHESIS; CELL MOTION; DRUG EFFECT; METABOLISM; OVARY TUMOR; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; ESTRADIOL; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UP-REGULATION;

EID: 65649135116     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819bcb75     Document Type: Article

References (49)

1. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature. 1977;265:69-72.
2. Morley P, Whitfield JF, Vanderhyden BC, et al. A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology. 1992;131:1305-1312.
3. Gu Q, Moss RL. 17β-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. J Neurosci. 1996;16:3620-3629.
4. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta. 1999;1411:334-350.
5. Owman C, Blay P, Nilsson C, et al. Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt's lymphoma and widely distributed in brain and peripheral tissues. Biochem Biophys Res Commun. 1996;228:285-292.
6. Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625-1630.
7. Thomas P, Pang Y, Filardo EJ, et al. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146:624-632.
8. Filardo EJ, Quinn JA, Bland KI, et al. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000; 14:1649-1660.
9. Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002;80:231-238.
10. O'Donnell AJ, Macleod KG, Burns DJ, et al. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer. 2005; 12:851-866.
11. Langdon SP, Hirst GL, Miller EP, et al. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol. 1994;50:131-135.
12. Choi KC, Kang SK, Tai CJ, et al. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology. 2001;142:2351-2360.
13. Lindgren P, Bäckström T, Mählck CG, et al. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol. 2001;19:31-38.
14. Mabuchi S, Ohmichi M, Kimura A, et al. Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines. Endocrinology. 2004;145:49-58.
15. Langdon SP, Gabra H, Bartlett JM, et al. Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res. 1998;4:2245-2251.
16. Hempling RE, Piver MS, Eltabbakh GH, et al. Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol. 1998;21: 447-451.
17. Munstedt K, Steen J, Knauf AG, et al. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer. 2000;89:1783
18. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des. 2003;9:1565-1574.
19. Guerrero J, Santibanez JF, Gonzáles A, et al. EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp Cell Res. 2004;292:201-208.
20. Jo M, Thomas KS, O'Donell DM, et al. Epidermal growth factor receptor-dependent and - independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem. 2003;278: 1642-1646.
21. Liu D, Aguirre Ghiso J, Estrada Y, et al. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell. 2002;1:445-457.
22. Danø K, Behrendt N, Høyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost. 2005;93:676-681.
23. Wahlberg K, Hoyer-Hansen G, Casslén B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res. 1998;58:3294-3298.
24. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57:25-40.
25. Borgfeldt C, Hansson SR, Gustavsson B, et al. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer. 2001;92:497-502.
26. Casslen B, Bossmar T, Lecander I, et al. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer. 1994;30A:1302-1309.
27. Henic E, Sixt M, Hansson S, et al. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Gynecol Oncol. 2006;101:28-39.
28. Psyrri A, Kassar M, Bamias A, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res. 2005;11:8637-8643.
29. Scambia G, Benedetti-Panici P, Ferrandina G, et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer. 1995;72:361-366.
30. Lau DH, Lewis AD, Ehsan MN, et al. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res. 1991;51: 5181-5187.
31. Casslen B, Nordengren J, Gustavsson B, et al. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor. J Clin Endocrinol Metab. 1995;80: 2776-2784.
32. Riisbro R, Piironen T, Brünner N, et al. Measurement of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay. 2002;25:53-56.
33. Bottalico B, Larsson I, Brodszki J, et al. Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies. Placenta. 2004;25:518-529.
34. Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab. 2005;16:362-367.
35. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-943.
36. Cunningham O, Andolfo A, Santovito ML, et al. Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. Embo J. 2003;22:5994-6003.
37. Pöllänen J, Hedman K, Nielsen LS, et al. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol. 1988;106:87-95.
38. Puri C, Tosoni D, Comai R, et al. Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Mol Biol Cell. 2005;16:2704-2718.
39. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402:884-888.
40. Sukocheva O, Wadham C, Holmes A, et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase. J Cell Biol. 2006;173:301-310.
41. Filardo EJ, Quinn JA, Frackelton AR, et al. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002;16:70-84.
42. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci. 2001;22: 368-376.
43. Sukocheva OA, Wang L, Albanese N, et al. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol Endocrinol. 2003;17:2002-2012.
44. Kang SK, Choi KC, Tai CJ, et al. Estradiol regulates gonadotropin- releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology. 2001;142:580-588.
45. Treeck O, Haldar C, Ortmann O. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep. 2006;15:231-235.
46. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol. 2002;84: 201-209.
47. Schwartz PE, Chambers JT, Kohorn EI, et al. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer. 1989;63:1074-1078.
48. Rendina GM, Donadio C, Giovannini M. Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma. Eur J Gynaecol Oncol. 1982;3:241-246.
49. Perillo B, Sasso A, ABbondanza C, et al. 17beta-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol. 2000;20:2890-2901.